Open AccessTransitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate Among Veterans with Schizophrenia
Author(s) -
Antoine C. El Khoury,
Charmi Patel,
Panagiotis Mavros,
Ahong Huang,
Li Wang,
Richa Bashyal
Publication year - 2021
Publication title -
neuropsychiatric disease and treatment
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.819
H-Index - 67
eISSN - 1178-2021
pISSN - 1176-6328
DOI - 10.2147/ndt.s313067
Subject(s) - medicine , paliperidone palmitate , retrospective cohort study , cohort , antipsychotic , schizophrenia (object oriented programming) , psychiatry
Compared to once-monthly paliperidone palmitate (PP1M), once-every-3-months paliperidone palmitate (PP3M) reportedly increases treatment adherence. The objective of this study was to compare treatment patterns, utilization, and costs among Veterans Health Administration (VHA) patients with schizophrenia who transitioned to PP3M versus those remaining on PP1M.